Panelists discuss how recent advancements in diagnostic strategies and emerging combination therapies are shaping the management of metastatic castration-sensitive prostate cancer to better address patient needs and improve outcomes.
The median number of re-injections was 6 (range, 1-12).
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in…
The European Association of Urology (EAU) Paediatric Urology Guidelines Panel has prepared these Guidelines with the aim of increasing the quality of care for children…
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Bladder cancer patients undergoing radical cystectomy face the challenge of not only coping with a cancer diagnosis, but also choosing a form of urinary diversion—a…
Cardiovascular health measure negatively linked to OAB, with partial mediation by weight-adjusted waist index
Proposed changes to HIPAA regulations are meant to strengthen cybersecurity protections for electronic protected health information.
Urology Practice, an official journal of the American Urological Association and companion toThe Journal of Urology, aims to give you the critical analysis and practical…
P2s: Practice Changing, Paradigm-shifting Clinical Trials in Urology (P2s) are designed to showcase the exceptional, groundbreaking studies that are expected to change the day-to-day practice…
